Insights gathered from patients are an invaluable asset for life sciences companies during all stages of product development and marketing.  Accurately compensating patients for their time, expertise, and lived experience has become an increasingly important task for compliance programs as the industry places greater emphasis on patient-centric approaches.

Historically, compensation models were relatively straightforward. However, as more patients become actively engaged in the different facets of the life sciences industry’s product life cycle—and as companies strive to better reflect the value different patients bring—compensation structures have evolved. This has led to the growing adoption of patient tiering systems, adding a new layer of intricacy to patient engagement and compensation.

 

Non-Tiered Patient Compensation

The more  traditional approach to patient compensation is the non-tiered model. In this arrangement, all patients receive the same rate regardless of their background or experience level. While the total engagement fee may vary depending on the type and duration of service—such as participating in advisory boards or surveys—the rate of pay remains uniform across all individuals involved in a given activity. This helps prevent overpayment or underpayment while simplifying the decision-making process for life science companies.

 

Tiered Patient Compensation

A more nuanced approach is the tiered compensation model, which adjusts payments based on a patient’s level of expertise and engagement. Implementing this model requires additional planning and criteria to differentiate patients and assign them to appropriate tiers, typically ranging from two to four levels.

The starting point for many tiering systems is the distinction between general patients and expert patients. Expert patients not only live with a specific condition but also bring added value through deeper involvement in healthcare advocacy, speaking engagements, collaborations with industry stakeholders, or leadership within patient communities. They often serve as thought leaders in their disease area and can provide unique insights during the drug and device development process.

Social media is one high profile tool that both provides a platform for patient thought leadership and allows companies to identify and assess patients with varying degrees of influence and value. However, it’s important to evaluate social media metrics critically. Factors such as follower count, engagement rate, and the relevance of posts to their disease area should all be considered carefully to avoid overemphasizing visibility in lieu of substance.

As the life sciences industry evolves toward more patient-inclusive research and business models, compensation strategies must adapt in tandem. Both non-tiered and tiered approaches offer distinct advantages, but the key lies in aligning the payment model with the goals of the engagement and the value provided by the patient.

A thoughtful, transparent, and fair approach to compensation fosters stronger relationships with patient partners. By carefully considering the diverse contributions of patients, companies can build compensation frameworks that are equitable, sustainable, and compliant.